SARS-CoV-2 Infection Clinical Trial
Official title:
COVID-19 Related Outcomes Among Cancer Patients Treated With TKIs, Including RegorafeNib or SorAfenib
This is an observational study in which data from people with cancer who had the Coronavirus disease 2019 (COVID-19) are collected and studied. In observational studies, only observations are made without specified advice or interventions. The most recently discovered coronavirus (SARS-CoV-2) may cause illness in humans ranging from the common cold to serious illness, also known as COVID-19. People with cancer are particularly at risk of becoming very sick with COVID-19, especially during or shortly after a cancer treatment. Several treatments for COVID-19 have been tested in clinical studies. However, people with cancer or with recent cancer treatments were usually excluded. Tyrosine kinase inhibitors (TKIs) are used to treat several cancer types. TKIs including regorafenib and sorafenib block certain proteins, which are involved in the growth of cancer. They also have an anti-inflammatory effect and may be able to block the entry of the coronavirus into the cell. This could possibly prevent infection. However, data on COVID-19 from people with cancer receiving TKIs are missing. The main purpose of this study is to find out whether COVID-19 outcomes were different in people with cancer receiving TKIs compared to those receiving other anti-cancer drugs. To do this, researchers will compare COVID-19 outcomes within 30 days of COVID-19 diagnosis between both groups. The data for the comparison will come from databases called Optum and MarketScan. Besides this data collection, no further tests or examinations are planned in this study. There are no required visits or tests in this study. Data will be from October 2019 to June 2021 or the latest available data.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
| Completed |
NCT04593641 -
This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)
|
Phase 1 | |
| Recruiting |
NCT05200754 -
Trial With or Without Infusion of SARS-CoV-2 Antibody Containing Plasma in High-Risk Patients With COVID-19
|
Phase 2 | |
| Completed |
NCT04583995 -
A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom
|
Phase 3 | |
| Recruiting |
NCT06255860 -
SARS-COV-2 Reinfection and Multisystem Inflammatory Syndrome in Children (MIS-C) Risk: Matched Case-control Study
|
||
| Recruiting |
NCT04516811 -
Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19
|
Phase 3 | |
| Recruiting |
NCT05012826 -
Osteopathy and Physiotherapy Compared to Physiotherapy Alone on Fatigue and Functional Status in Long COVID
|
N/A | |
| Completed |
NCT05007236 -
Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection.
|
Phase 2 | |
| Recruiting |
NCT06026514 -
Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults
|
Phase 1 | |
| Completed |
NCT05523739 -
Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients
|
Phase 1 | |
| Suspended |
NCT04738136 -
Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia
|
Phase 2 | |
| Recruiting |
NCT04584658 -
Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19) Infection (DYADS Study)
|
||
| Recruiting |
NCT04547114 -
Breath Analysis for SARS-CoV-2 in Infected and Healthy Subjects
|
||
| Completed |
NCT05119348 -
Transmission of Coronavirus Disease 2019 (COVID19) in Crowded Environments
|
N/A | |
| Completed |
NCT05096962 -
COVID-19: SARS-CoV-2-CZ-PREVAL-II Study
|
||
| Recruiting |
NCT04534400 -
Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure
|
||
| Completed |
NCT04527354 -
Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia
|
Phase 2 | |
| Completed |
NCT04583982 -
ImmuneSense™ COVID-19 Study
|
||
| Completed |
NCT05077176 -
Phase 3 Booster Vaccination Against COVID-19
|
Phase 3 | |
| Completed |
NCT05584189 -
COVID-19 MP Biomedicals Rapid SARS-CoV-2 Antigen Test Usability
|
N/A |